ReviewNature reviews. Cardiology2014
Cardiovascular manifestations of the emerging dengue pandemic.
Review in Nature reviews. Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2025Pooled it
- Global epidemiology of myocarditis: disparities in age, sex and geography.Nature reviews. Cardiology · 2026Review
- Dengue virus infection.Nature reviews. Disease primers · 2026Review
- Amazonian toxoplasmosis complicated by severe hypoxemic pneumonia and myopericarditis in an immunocompetent adult.BMC infectious diseases · 2026Article
- Position Statement on the Management of Antithrombotic and Anticoagulant Therapy in Dengue - 2026.Arquivos brasileiros de cardiologia · 2026Article
- Serial bedside echocardiography identifies children at risk of recurrent Dengue shock: a prospective cohort study.BMC emergency medicine · 2026Article
- Complications, Deaths, and Disability Burden in the 2 Years Following Dengue Infection.JAMA network open · 2026Article
- Supraventricular Tachycardia as an Uncommon Presentation of Dengue Myocarditis.JACC. Case reports · 2025Article
- Fulminant myocarditis associated with severe dengue in a young patient from the Peruvian Amazon: case report and literature review.Revista peruana de medicina experimental y salud publica · 2025Review
- Cardiovascular complications in acute dengue infection: a population-based cohort study.The Lancet regional health. Western Pacific · 2025Article
- An artificial intelligence-based approach to identify volume status in patients with severe dengue using wearable PPG data.PLOS digital health · 2025Article
- Role of Extracellular Vesicles in Severe Dengue: Virus-Host Interactions and Biomarker Potential.Viruses · 2025Review
- Wait and trust: conservative management of bradyarrhythmias due to dengue infection: a case report.European heart journal. Case reports · 2025Article
- MALAT1 and HIST1H2BC as connecting diagnostic biomarkers in Ebola and its overlapping disease: An integrative approach.Bioinformation · 2025Article
- Dengue Envelope Protein as a Cytotoxic Factor Inducing Hemorrhage and Endothelial Cell Death in Mice.International journal of molecular sciences · 2024Article
- Article
- Review
- Dengue.Lancet (London, England) · 2024Review
- Review
- Severe dengue in the intensive care unit.Journal of intensive medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Dengue is one of the most important emerging viral diseases globally. The majority of symptomatic infections result in a relatively benign disease course. However, a small proportion of patients develop severe clinical manifestations, including bleeding, organ impairment, and endothelial dysfunction with increased capillary permeability causing hypovolaemic shock that can lead to cardiovascular collapse. Evidence is increasing that dengue can also cause myocardial impairment, arrhythmias and, occasionally, fulminant myocarditis. No antiviral agents or vaccines are licensed for dengue, and treatment remains supportive with judicious fluid replacement for patients with severe disease. Defining the role of cardiac dysfunction in the haemodynamic compromise of severe dengue has potentially important management implications. In this Review, we will outline the current understanding of the cardiovascular manifestations of dengue, including myocardial and vascular involvement, and conclude with a discussion of the available therapeutic options and potential future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.